Skip to main content

Advertisement

SpringerLink
Log in

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The combination of carfilzomib, lenalidomide, and dexamethasone (CRd) has induced deep responses in patients with newly diagnosed multiple myeloma. While vascular endothelial growth factor (VEGF) pathway polymorphisms have been associated with clinical outcomes for antiangiogenesis agents, we explored associations between such polymorphisms and CRd clinical response. The VEGF-1498C>T (rs833061) and VEGFR2 V297I (rs2305948) were associated with CRd response (OR ≤ 0.10, P ≤ 0.009), whereas VEGF-1498C>T and VEGFR2 Q472H (rs1870377) were associated with minimum residual disease negativity (P ≤ 0.023). As these SNPs were not associated with disease parameters (e.g., plasma VEGF, albumin, or beta-2-microglobin concentration), data suggest these SNPs may be markers of CRd response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sorensen FB, Abildgaard N (2005) Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 128:210–217

    Article  CAS  PubMed  Google Scholar 

  2. Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N, Vangsted AJ (2012) Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer 131:E636–E642

    Article  CAS  PubMed  Google Scholar 

  3. Brito AB, Lourenco GJ, Oliveira GB, De Souza CA, Vassallo J, Lima CS (2014) Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma. Ann Hematol 93:1363–1369

    CAS  PubMed  Google Scholar 

  4. De Luisi A, Ferrucci A, Coluccia AM, Ria R, Moschetta M, de Luca E, Pieroni L, Maffia M, Urbani A, Di Pietro G, Guarini A, Ranieri G, Ditonno P, Berardi S, Caivano A, Basile A, Cascavilla N, Capalbo S, Quarta G, Dammacco F, Ribatti D, Vacca A (2011) Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res 17:1935–1946

    Article  PubMed  Google Scholar 

  5. Escudier B, Rini BI, Motzer RJ, Tarazi J, Kim S, Huang X, Rosbrook B, English PA, Loomis AK, Williams JA (2015) Genotype correlations with blood pressure and efficacy from a randomized phase III trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma. Clin Genitourin Cancer

  6. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD (2010) Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 29:95

    Article  PubMed  PubMed Central  Google Scholar 

  7. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD (2009) The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 8:2496–2508

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O (2015) Treatment with carfilzomib–lenalidomide–dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol

  9. Martiniani R, Di Loreto V, Di Sano C, Lombardo A, Liberati AM (2012) Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol 2012:842945

    PubMed  PubMed Central  Google Scholar 

  10. Metzger CS, Koutsimpelas D, Brieger J (2015) Transcriptional regulation of the VEGF gene in dependence of individual genomic variations. Cytokine 76:519–526

    Article  CAS  PubMed  Google Scholar 

  11. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Kyle RA, Gertz MA, Greipp PR (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6:3111–3116

    CAS  PubMed  Google Scholar 

  12. Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A (2010) The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 117:109–116

    Article  CAS  PubMed  Google Scholar 

  13. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A, Investigators A (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372:142–152

    Article  PubMed  Google Scholar 

  14. Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, Qin Q, Zhao B, Yang Y, Hui R (2007) Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 50:760–767

    Article  CAS  PubMed  Google Scholar 

  15. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232–1235

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology Program, Office of the Clinical Director, National Cancer Institute, 9000 Rockville Pike, Building 10, Rm 5A01, Bethesda, MD, 20892, USA

    Tristan M. Sissung, Cody J. Peer & William D. Figg

  2. Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Neha Korde, Sham Mailankody & Ola Landgren

  3. Myeloma Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

    Dickran Kazandjian

  4. Biostatistics and Data Management, National Cancer Institute, Bethesda, MD, USA

    David J. Venzon

Authors
  1. Tristan M. Sissung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cody J. Peer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neha Korde
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sham Mailankody
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dickran Kazandjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David J. Venzon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ola Landgren
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. William D. Figg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William D. Figg.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to disclose.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 112 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sissung, T.M., Peer, C.J., Korde, N. et al. Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Cancer Chemother Pharmacol 80, 217–221 (2017). https://doi.org/10.1007/s00280-017-3323-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-017-3323-8

Keywords

Search

Navigation